The Science Journal of the Lander
College of Arts and Sciences
Volume 13
Number 2 Spring 2020
2020

Causes and Mechanisms of Crohn’s Disease
Chana Weis
Touro College

Follow this and additional works at: https://touroscholar.touro.edu/sjlcas
Part of the Biology Commons, and the Pharmacology, Toxicology and Environmental Health
Commons

Recommended Citation
Weis, C. (2020). Causes and Mechanisms of Crohn’s Disease. The Science Journal of the Lander College
of Arts and Sciences, 13(2). Retrieved from https://touroscholar.touro.edu/sjlcas/vol13/iss2/9

This Article is brought to you for free and open access by the Lander College of Arts and Sciences at Touro Scholar.
It has been accepted for inclusion in The Science Journal of the Lander College of Arts and Sciences by an
authorized editor of Touro Scholar. For more information, please contact touro.scholar@touro.edu.

-

Causes and Mechanisms of Crohn’s Disease
Chana Weis
Chana Weis will graduate fall 2021 with a Bachelor of Science degree in Honors Biology

Abstract
Crohn’s disease and ulcerative colitis are the two most prevalent inflammatory bowel diseases (IBDs) in Jewish and Caucasian populations, affecting as many as one in 250 individuals. Nevertheless, the underlying causes of both disorders are not yet fully understood
and remain unknown. However, current evidence suggests that the exaggerated inflammatory response, more commonly referred
to as IBD, is believed to arise from dysregulation of the gastrointestinal (GI) immune system in genetically predisposed individuals
who are exposed to environmental triggers. Recent advances have identified multiple IBD susceptibility genes; however, only a few
environmental determinants of IBD have been consistently identified. The difficulty in understanding the etiology of IBD is in part
due to the complex interactions between genes and the environment. Additionally, autoimmune mechanisms are believed to play
a role in the development of IBDs, but the target antigens and the underlying pathways have not been sufficiently characterized
and identified. IBD is commonly referred to as an “idiopathic disease;” a disease with an unknown cause (Health &Medicine, 2016;
Sartor, 2006).This paper examines the possible causes of IBD, specifically highlighting Crohn’s disease.
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Introduction
Crohn’s Disease (CD) is a chronic autoimmune disease
mainly affecting the gastrointestinal (GI) tract extending
from the mouth to the anus; however, it’s most commonly found in the ilium, leading to the alternate name
ileitis (Newman & Siminovitch, 2003). It’s characterized
by thickened areas of the GI wall with inflammation
extending through all four layers including the mucosa,
submucosa, muscularis externa, and serosa (Politics &
Government week, 2017; Ruthruff, 2007). The inflammation is somewhat similar to that of ulcerative colitis,
and commonly leads to abdominal pain, diarrhea, vomiting, weight loss, anemia and fever (Torres et al. 2017).
However, some patients may experience mouth and skin
sores along with joint stiffness and swelling (Creek, 2017).
Unfortunately, patients suffering from CD are at a higher
risk of developing other autoimmune disorders such as
osteoporosis, thyroid disease, as well as colorectal cancer (Baumgart & Sandborn, 2012; O’Sullivan, 2009; Bae
et al. 2014). Symptoms range from mild to severe and
treatment varies depending on the severity of the disease.
Typically, a doctor will perform a series of tests before
confirming CD. These tests may include a physical exam,
lab tests, stool samples, CT scans, MRI, endoscopy and
a colonoscopy (Baumgart & Sandborn, 2012), in which
a small flexible camera is inserted through the rectum
to distinguish abnormalities. Together, these tests detect
abnormalities which may exist throughout the intestinal
track thus indicating IBD.
While there is currently no known cure for CD, treatment options are available (Akobeng, 2008; Michail et al.
2013). It is estimated that roughly ten percent of patients
who undergo surgery will have prolonged clinical remission (Baumgart, 2012; D’Incà & Caccaro, 2014). The goal
58

of treatment is to reduce inflammation and to improve
the prognosis by limiting complications (Newman &
Siminovitch, 2003). Noninvasive treatment options include anti-inflammatory medication, antibiotics, and immunosuppressant drugs. Anti-inflammatory medication
controls and suppresses inflammation, thereby decreasing
the frequency of flare ups. With proper treatment over
time, periods of remission can be extended, and flare ups
can be reduced. Alternatively, immunosuppressant medications, such as corticosteroids, aid by suppressing the
immune system, thus allowing the intestinal tissue to heal.
However, in some instances, more invasive treatment
plans are required. Despite significant progress in treatments for CD, it’s estimated that as many as seventy-five
to ninety percent of patients suffering from the disease
will undergo surgery to relieve symptoms at some point
during the patient’s life. (Politics & Government Week,
2017; Liu et al. 2017). At times, CD creates complications
that are deemed a medical emergency, such as a bowel
abscess, a fistula (which may result from an unaddressed
abscess), uncontrolled bleeding, or intestinal blockage, in
which case surgery may be required. As an aside, patients
may also require surgery as a result of previous medications having caused severe side effects, or simply because
the medications have stopped working as effectively as
the body adapts and immunizes itself against the medication (Torres et al. 2017).
There are several types of surgeries that can be performed, the most common one being a bowel resection.
This involves the removal of all parts of the damaged intestine and is performed when parts of the small bowel
are diseased or blocked (Simon et al. 2003). A partial
colectomy is another type of bowel resection in which
the surgeon removes the damaged parts of the colon. It
can be performed openly or laparoscopically. When performed openly, the surgeon manually cuts an extensive
incision; alternatively, the surgeon may prefer to work
laparoscopically, making several small incisions, thereby
allowing him to work outside the body. In some instances, a total colectomy is required in which the surgeon

Causes and Mechanisms of Crohn’s Disease

removes the entire colon. This is generally required only
in severe cases in which the colon is highly inflamed, and
medication is ineffective (Travis, et al. 2011). A colectomy
often requires further procedures to reattach the disconnected portions of the digestive system, thus permitting
waste to leave the body. For example, in some instances,
an ostomy is performed. This surgery is categorized as
a lifesaving procedure as it is performed when stool is
unable to be eliminated from the body through the rectum (Travis et al. 2011). In this procedure, the colon is
removed, and a stoma is created on the abdomen.Wastes
are then allowed to pass through the surgically created
stoma into an ostomy bag, a prosthetic bag which holds
stool and can be emptied regularly.
Common risk factors of these surgeries include bleeding, bowel obstruction, infection and pulmonary embolism.
Methods
Data was collected using ProQuest and PubMed databases through Touro College’s online library. Among the
key-phrases used were “Crohn’s Disease”,“irritable bowel
disorder”, “epigenetics”, as well as “hygiene hypothesis.”
Genetic Factors
There is a significant amount of evidence suggesting that
genetic factors play a key role in the triggers of IBD. Genetic
mutations lead to the body’s defective defense against microbes in the digestive system, allowing the immune system
to attack the lining of the digestive tract, thereby causing
inflammation indicating IBD.The genetic analysis of complex
diseases, such as IBD, is difﬁcult to identify for several reasons. First, the disease isn’t categorized into a single entity,
but rather into groups of heterogeneous disorders, where
environmental and genetic factors play a signiﬁcant role in
disease expression. Additionally, ethnic differences that may
exist between patients suffering with IBD are associated
with different mutations (Bae et al. 2014). Other difficulties
faced include the relatively low frequency of IBD, about .1-.4
percent, amongst populations (Michail et al. 2013); statistics
showing that only about ten percent, ﬁrst-degree relatives
are affected with the same disorder (Sartor, 2006; Pena,
1998); as well as the presence of genes with minor genetic
effects, are some of the difﬁculties faced with when identifying disease susceptibility. Nevertheless, there is an emerging
understanding of the inherited aspects that predispose an
individual to IBD (Newman & Siminovitch, 2003).
The evidence for genetic involvement in IBD comes from
ethnic e.g., Ashkenazic Jews and family-based studies on
blood relatives affected with CD, associations of IBD with
known genetic syndromes, diseases with known genetic
predisposition such as autoimmune diseases, and more

recently through genetic marker studies (Barber GE,Yajnik
V, Khalili H, et al. 2016).Various genetic markers have shown
different levels of correlation with IBD. Some have failed
to show a consistent association with IBD, including blood
groups, secretor status, a 1-antitrypsin, and immunoglobulin
marker genes. Studies on these markers can be divided into
those in which a genetic element is proven and those in
which a genetic predisposition may be present (Pena,1998).
Several polymorphisms in the genes encoding different cytokines and their receptors have been described and are
potential candidates to be studied scientifically.
There are currently multiple studies being carried out
to help identify the genetic mutations, causes, and susceptibility in developing IBD. In addition, technological progress
in genetic testing and DNA sequencing permitted many
genome-wide association studies (GWAS), which helped
identify new single nucleotide polymorphisms (Loddo
& Romano, 2015). Correspondingly, over the past few
decades, there have been significant advances in the understanding of genetic causes linked to IBD. (Newman &
Siminovitch, 2003). The studies described below are population-based studies in areas that extend over a period of
time, making them most likely to give fair, unbiased results.
These studies have conﬁrmed the increased prevalence
of IBD in family members as compared to those in the
general population. These include studies based on twins,
families, and the Jewish Ashkenazic ethnic group.
The data derived from studies performed on twins powerfully supports the view that IBD is linked to a genetic
component. There is a signiﬁcant increase in the concordance of IBD in monozygotic twins compared to dizygotic
twins, particularly with Crohn’s disease. Twin studies for
CD have shown fifty percent concordance in monozygotic twins compared to less than ten percent in dizygotic
twins (Loddo & Romano, 2015). Environment plays only a
negligible role in predisposition for CD. Indirect evidence
supporting the necessity of predisposing genes for the development of the disease in the presence of a common
environment is the low prevalence in spouses of patients
with IBD. Spouses who both suffer from CD, is deemed as
a highly unusual occurrence, as frequent as can be expected by chance alone (Dudley, 1995)
Family-based studies consist of studying linkage analysis
in sibling pairs and parental transmission in genome-wide
screening using microsatellite markers. Microsatellite
markers, otherwise known as simple sequence repeats
(SSRs), which can be defined as segments of DNA where
the nucleotide sequence repeats. Familial aggregation of
IBD has been well documented in North American and
European studies. It is well established that first degree
relatives, particularly siblings, are at much greater risk in
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developing IBD as compared to those in the general population. For example, if one parent has CD, the child has
a ten percent increased risk in developing CD; and even
if both parents suffer from CD, that likelihood increases
to thirty-five percent (Pena, 1998). It has been shown that
siblings of patients suffering from CD experience a seventeen to thirty-five times greater likelihood of developing
CD (Akobeng, 2008).
Another significant study performed on ethnic populations proved that genetic variants are indeed associated
with CD. People of Ashkenazi Jewish heritage have an increased risk and a higher prevalence in developing CD
as compared to non-Jews (Baumgart & Sandborn, 2012;
Newman & Siminovitch, 2003). Several studies have proven that CD is two-to-four times more prevalent among
individuals of Jewish decent compared to non-Jewish
Europeans living in the same area (NewsRX Health &
Science, 2012). Currently, there are seventy-one genetic variants that have been identified in Ashkenazi Jewish
ancestry that increase an individual’s risk of developing
CD. (Baumgart & Sandborn, 2012). In a study performed
examining over six thousand individuals whose Jewish ancestry was confirmed by a large number of genetic markers, several variants were detected that are associated
with the increased risk of CD. The involvement of twelve
recognized CD risk variants in Ashkenazi Jews was confirmed and identified in novel genetic regions, as opposed
to in non-Jewish European populations (Kenny et al. 2012).
Further studies of these regions may aid in the discovery
of biological pathways affecting susceptibility to CD and
lead to the development of innovative and more effective
treatments. This study not only proves the genetic origin
of CD, but also demonstrates the value of genetic studies
in secluded ethnicities, such as the Ashkenazim. Jewish
heritage is an independent risk factor for developing CD.
Genetic anticipation is the earlier onset of a disease in
the offspring of parents with the disorder; a phenomenon
featured in other genetic diseases, it has now been identified in Crohn’s (Polito et al. 1996).
While genetic studies have been highly successful at
identifying the genetic risk factors for CD, these studies
have proven virtually nothing about why one person will
exhibit only mild symptoms of CD while another patient
may require surgery to treat their condition. However, a
familial link is often noticed in the symptoms of related
patients. Researchers recognize that family members with
CD often tend to have similar progress through treatments (NewRX, 2017). Furthermore, researchers looked
at the genome of two thousand seven hundred patients
who shared similar symptoms and severity of CD. By comparing these patient’s DNA, the researchers discovered
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four genetic variants including FOX10, IGFBP1, MHC, and
XACT that influence the severity of a patient’s condition.
Strikingly, none of these genes have been shown to affect
the risk of developing CD.This fact suggests that it is likely
that genetics not only plays a role in the diagnosis of CD,
but in the patient’s prognosis as well (Obesity, Fitness &
Wellness Week, 2017).
Environmental Factors
Although the precise cause for CD is unknown, it’s believed that environmental factors also play a role in
the development of the disease. Several environmental
risk factors, such poor diet, as well as the side effects
of breastfeeding, smoking, stress, and drugs, are believed
to trigger inflammation. Additionally, childhood exposure
towards an overly hygienic environment, seem to allow
CD to manifest in predisposed patients.
Food is believed to promote the maintenance of gut
integrity. Although the direct cause and effect relationship
between the gut microbiota and IBD is unclear, targeting
the intestinal microbiota allows for prevention of disease,
as well as potential research concerning new treatments.
Diet plays a significant role in a patient suffering from
CD, as the body is unable to digest and absorb food appropriately, thereby causing malnourishment in patients
with CD (O’Sullivan, 2009). Furthermore, many patients
with CD are anemic, as well as deficient in vitamin D, folic
acid and vitamin B12 (Torres et al. 2017; Creek, 2017).
Patients are recommended to avoid certain foods such as
raw fruits and vegetables, dairy, fatty, greasy, spicy, and high
fiber foods, as these foods are more difficult for the body
to digest and absorb, and commonly irritate the bowel
(Livie et al. 2006). While it has not been proven that a
poor diet is a direct cause of CD, research has shown a
common thread, that a proper diet is helpful in several
ways by reducing one’s predisposition to developing CD.
Moreover, diet has also been used as a treatment option
for CD (Akobeng, 2012). Similar research has proven that
maintaining a healthy diet is equally as effective in putting
a patient in remission as corticosteroid treatments, particularly in the case of children (BMJ, 1997). Nutritional
repletion is effective both by affecting the gut mucosa
as well as by decreasing intestinal permeability. There is
some evidence that the enteral diet has a direct effect on
the gut mucosa by reducing cytokine production and the
accompanying inflammation, thus leading to decreased
intestinal permeability (Hanaway, 2006).
Breastfeeding promotes colonization with microbiota
such as Bifidobacteria by providing them with the HMOs
(human milk oligosaccharides) they require to thrive.
According to one study, when specific HMOs, GOSs
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(short-chain galactooligosaccharides) and FOSs (long-chain
fructooligosaccharides), were fed to infants in the first six
months of life, they later had fewer incidences of autoimmune reactions linked to gut microbiota, including recurrent wheezing, and allergic urticaria. Accordingly, Crohn’s
which is an autoimmune disease, may be affected similarly
by breastfeeding (Torres, et al. 2017). Maternal secretory
IgA, a component of breast milk has been proven to affect the composition of intestinal microbiota and the expression of genes associated with intestinal inflammation.
Additionally, a negative correlation has been found between
infants’ exposure to breast milk and the development of
early onset IBD, suggesting breastfeeding has a preventative
effect on IBD development (Stiemsma et al. 2015).
While cigarette smoking is notorious for initiating
health risks such as lung cancer and heart disease, it is
believed to play a role in the development of IBD as well.
Although the pathogenesis for IBD is unclear, cigarette
smoking is associated with IBD outcomes as it exacerbates the condition. Analysis of multiple studies has confirmed that active smokers are at increased risk for acquiring CD (Newman & Siminovitch, 2003). Furthermore,
smoking has repeatedly been proven to worsen the prognosis of CD as it promotes a fistulizing phenotype, aggravates disease course, and produces a decreased response
to medical treatment. (Ole et al. 2009). Interestingly, while
smoking has negative ramifications for Crohn’s sufferers,
it may have a protective effect on those with a genetic
disposition towards UC. Active smokers were proven to
be at a lower risk for developing UC in comparison to
those who never smoked and those who quit smoking.
This phenomenon may be linked to nicotinic acetylcholine receptors, which are present in mucosal epithelial
cells of the bowel, as well as on T cells. However, clinical
trials of nicotine replacement in IBD have only yielded a
modest benefit at best; thus, nicotine alone may not be
the driving factor (Ole et al. 2009).
Despite the significant consequences of smoking associated with patients suffering from IBD pathogenesis, the
highest incidence of CD occurs in countries with a low
prevalence of smoking such as United States and Canada
(Rook, 2012). Furthermore, the majority of patients with
CD are not current smokers and the majority of smokers
do not develop CD, proving that smoking or lack thereof
likely plays a role in the pathogenesis of only a subset of
IBD patients (Torres et al. 2017). These studies display little
correlation between smoking and IBD. Nonetheless, all IBD
patients should be encouraged to quit smoking due to the
deleterious negative health effects associated with smoking.
The role of psychological distress and personality as
predisposing factors for the development of CD remains

controversial. The debate concerning this matter has
been ongoing for over eighty years without reaching a
common ground, as attempts to investigate the role of
psychological factors have unveiled conflicting results.
However, over the past several years, it has become evident that psychological stress is at least associated with
CD. However, that stress may be the result rather than
the cause of chronic and longstanding CD. Unpredictable
flare-ups and changes in body image can also lead to additional stress. This stress may precipitate an exacerbation
of the disorder, thus continuing a vicious cycle of flare ups.
Multiple theories have been presented suggesting explanations on the unknown environmental exposures
that may interact with the immune system and result in
abnormal inflammatory intestinal response. However, the
most predominant theory is the hygiene hypothesis, which
explains the link between exposure to specific microbial allergies and the prevention of certain diseases. This
hypothesis theorizes that when one’s childhood has had
excess hygiene and a lack of exposure to enteric pathogens; the child may not develop sufficient immunity towards pollution and environmental contamination. Thus,
it will inevitably impair microbial competence of the GI
immune system and its ability to recognize new antigens,
thereby predisposing children to immunologic disorders
further on in life (Sabe et al. 2017). While the effect of
lack of exposure is believed to be most profound during
early childhood, the ideal timing and degree of exposure
required remains unclear. The hygiene hypothesis also
theorizes that multiple childhood infections and poor hygiene protects and prevents an individual from developing
Crohn’s disease by allowing the host to develop tolerance
or immunity to agents that may trigger Crohn’s disease
later on in life (Stiemsma et sl. 2015). Additionally, it is
entirely probable that the impact of various exposures
are not mutually exclusive; such that disease development
depends on the dose-response interactions between exposures, and this reflects how strongly one’s exposure
may protect or increase the risk conferred by CD susceptibility mutations) (Sabe et al. 2017).
Interestingly, the ﬁrst Crohn’s disease gene identiﬁed,
CARD 15(caspase-activation recruitment) also referred
to as the NOD2 (nucleotide oligomerization domain
gene), found within IBD1 locus is involved with the innate immune system and the response of monocytes
upon perceiving a bacterial encounter. The abnormal
and unconstrained inﬂammatory response that may
occur in individuals with NOD2/CARD15 mutations is
likely to be involved with the pathogenesis of Crohn’s
disease. Polymorphisms in the CARD15/NOD2/IBD1
locus have been associated with the highest risk for CD
61

Chana Weis

development. Recent evidence shows that polymorphisms
cause reduced functionality of the immune system and
exacerbated phenotype (Newman & Siminovitch, 2003).
Counterintuitively, countries with poor sanitary conditions such as Africa and the Middle East reportedly have
a relatively low frequency of Crohn’s disease (Torres et
al. 2017), while more developed countries such as Canada
and the United States have the highest rates of CD. It is
believed that endemic parasitic infections may favorably
affect the immune system as to prevent disease by stimulating T-helper type2 (Th-2) cells, which in turn downregulate Th-1 cells and prevent the exaggerated Th-1 response associated with Crohn’s disease. Building on this
theory, the ova of Trichuris suis (eggs of a pig whipworm),
have been successfully used to treat Crohn’s disease
patients, as the intake of these parasites elicit Th-2 cells
thereby suppressing Th-1 cells from activating (Guarneret
et al. 2006; Summers, et al. 2005).
Many physicians treating patients with IBD do not believe that stress or diet are direct causes of IBD. Yet, due
to the lack of understanding of the etiology of IBD, no
known direct cause and cure exist for the disease. The
Crohn’s and Colitis Foundation and medical researchers
suggest that foreign substances found in the environment
or external agents such as bacteria may interact with a
weak immune system, thereby producing an immune response of inflammation which the body is unable to stop
(McGovern, Gardet, Törkvist, et al. 2007).
Epigenetics
It has become apparent that epigenetics plays a significant
role contributing to the development of CD. Epigenetics
can be defined as mitotically heritable changes in gene
expression without shifting the DNA. Gene expression
can be altered by changes to the structure and function of
chromatin. Different cells in the body are characterized by
different functions and different levels of gene expression
despite each sharing the same genetic code.This variation
in gene activity from cell to cell is achieved by mechanisms and processes that are collectively termed epigenetics. The main epigenetic mechanisms include DNA
methylation, histone modification, RNA interference, and
the positioning of nucleosomes. These epigenetic mechanisms, in particular DNA, allow the onset and reactivation
of disease that’s triggered by environmental factors that
rapidly break the mucosal barrier, thus stimulating an immune response or altering the balance between beneficial
and pathogenic enteric bacteria. Different genetic abnormalities can lead to similar disease phenotypes; these
genetic changes can be broadly characterized as causing
defects in mucosal barrier function, immunoregulation
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or bacterial clearance. These new insights will help develop better diagnostic approaches that identify clinically
important subsets of patients for whom the natural history of disease and response to treatment are predictable. Methylation appears to be of great importance in
the interaction between genome and the environment.
Variation in DNA methylation is a well-recognized cause
of human disease and is likely to play a pivotal role in the
cause of complex disorders such as CD.
Discussion and Conclusion
Inflammatory bowel disease is sectioned into two divisions,
CD and UC. Both are complex multifactorial disorders
characterized by chronic relapsing intestinal inflammation.
However, the etiology of both diseases remains largely
unknown as it is characterized as an idiopathic disease
(Sartor, 2006). Understanding the causes and molecular
mechanisms of CD and UC is a leading challenge in gastroenterology research, due in part to the relatively low
frequency of these disorders. Although significant effort
has been made to help identify genetic and environmental
factors that may increase the risk of IBD, little is known
about IBD-specific factors. Recent research has suggested
that IBD is caused by a complex interplay between genetic
predispositions of various genes, combined with an abnormal interaction with environmental factors as a result of
a perceived threat. Epidemiological evidence for a genetic
contribution is made apparent by twin and family studies
of CD patients. Genetic variants that stimulate IBD have
a substantial effect on gene function. These variants are
so rare in allele frequency, that the genetic signals aren’t
detected in genome-wide association studies of patients
with IBD. With recent advances in sequencing techniques,
roughly fifty genetic disorders have been identified and
associated with IBD such as osteoporosis as well as thyroid disease. Monogenic defects have been found to alter
intestinal immune homeostasis through many mechanisms.
Candidate gene resequencing should be carried out in early-onset patients in clinical practice.
The evidence that genetic factors are the prime contributors to disease pathogenesis confirms the insignificant
role of microbial and environmental factors. Epigenetic
factors can mediate interactions between environment
and genome. Epigenetic mechanisms could affect development and progression of IBD. Epigenomics is an emerging
field, and future studies could provide further insight into
the pathogenesis of IBD.
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